Maurice Jc Van Der Sangen

List of Publications by Year
in descending order

44 papers	2,306 citations	361296 20 h-index	265120 42 g-index
45 all docs	45 docs citations	45 times ranked	2716 citing authors

#	Article	IF	Citations
1	Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. Journal of Clinical Oncology, 2020, 38, 1763-1773.	0.8	665
2	Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. Journal of Clinical Oncology, 2021, 39, 1995-2004.	0.8	291
3	Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. Journal of Clinical Oncology, 2022, 40, 1220-1230.	0.8	274
4	Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study). Journal of Clinical Oncology, 2021, 39, 2816-2824.	0.8	151
5	Clinical management of women with metastatic breast cancer: a descriptive study according to age group. BMC Cancer, 2006, 6, 179.	1.1	114
6	Uncommon breast tumors in perspective: Incidence, treatment and survival in the Netherlands. International Journal of Cancer, 2007, 121, 127-135.	2.3	114
7	Reducing interobserver variation of boost-CTV delineation in breast conserving radiation therapy using a pre-operative CT and delineation guidelines. Radiotherapy and Oncology, 2012, 103, 178-182.	0.3	56
8	Long-term survival improvement in oesophageal cancer in the Netherlands. European Journal of Cancer, 2018, 94, 138-147.	1.3	56
9	Significance of breast boost volume changes during radiotherapy in relation to current clinical interobserver variations. Radiotherapy and Oncology, 2009, 90, 60-65.	0.3	53
10	SUBMIT: Systemic therapy with or without up front surgery of the primary tumor in breast cancer patients with distant metastases at initial presentation. BMC Surgery, 2012, 12, 5.	0.6	46
11	Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2â€“Positive Esophageal Adenocarcinoma: TRAP Study. Journal of Clinical Oncology, 2020, 38, 462-471.	0.8	44
12	Target volume delineation in external beam partial breast irradiation: Less inter-observer variation with preoperative- compared to postoperative delineation. Radiotherapy and Oncology, 2014, 110, 467-470.	0.3	41
13	A randomized controlled phase III multicenter study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer: ARTDECO study.. Journal of Clinical Oncology, 2020, 38, 281-281.	0.8	41
14	Lack of Polymorphism in MUC1 Tandem Repeats in Cancer Cells is Related to Breast Cancer Progression in Japanese Women. Breast Cancer Research and Treatment, 2005, 92, 223-230.	1.1	33
15	Detection, treatment, and outcome of isolated supraclavicular recurrence in 42 patients with invasive breast carcinoma. Cancer, 2003, 98, 11-17.	2.0	29
16	Development and evaluation of radiotherapy deep learning dose prediction models for breast cancer. Physics and Imaging in Radiation Oncology, 2021, 17, 65-70.	1.2	28
17	Breast Cancers Found by Screening: Earlier Detection, Lower Malignant Potential or Both?. Breast Cancer Research and Treatment, 2002, 76, 19-25.	1.1	27
18	Adaptive radiation therapy for breast IMRT-simultaneously integrated boost: Three-year clinical experience. Radiotherapy and Oncology, 2012, 103, 183-187.	0.3	27

#	Article	IF	Citations
19	Radiation dose does not influence anastomotic complications in patients with esophageal cancer treated with neoadjuvant chemoradiation and transhiatal esophagectomy. Radiation Oncology, 2015, 10, 59.	1.2	26
20	Dose, fractionation and overall treatment time in radiation therapy â€" the effects on local control for cancer of the larynx. Radiotherapy and Oncology, 1994, 30, 97-108.	0.3	25
21	The rationale for and long-term outcome of incomplete axillary staging in elderly women with primary breast cancer. European Journal of Surgical Oncology, 2018, 44, 1714-1719.	0.5	15
22	Transformation of the National Breast Cancer Guideline Into Data-Driven Clinical Decision Trees. JCO Clinical Cancer Informatics, 2019, 3, 1-14.	1.0	15
23	Trends and variations in treatment of stage Iâ€"III non-small cell lung cancer from 2008 to 2018: A nationwide population-based study from the Netherlands. Lung Cancer, 2021, 155, 103-113.	0.9	14
24	Artificial intelligence based treatment planning of radiotherapy for locally advanced breast cancer. Physics and Imaging in Radiation Oncology, 2021, 20, 111-116.	1.2	13
25	Detection of local recurrence following breast-conserving treatment in young women with early breast cancer: Optimization of long-term follow-up strategies. Breast, 2013, 22, 351-356.	0.9	11
26	Heart position variability during voluntary moderate deep inspiration breath-hold radiotherapy for breast cancer determined by repeat CBCT scans. Physica Medica, 2017, 40, 88-94.	0.4	11
27	Implementation of a regional video multidisciplinary team meeting is associated with an improved prognosis for patients with oesophageal cancer A mixed methods approach. European Journal of Surgical Oncology, 2021, 47, 3088-3096.	0.5	9
28	Influence of histology on the effectiveness of adjuvant chemotherapy in patients with hormone receptor positive invasive breast cancer. Breast, 2011, 20, 505-509.	0.9	8
29	No prevention of radiotherapy-induced alopecia by scalp cooling. Radiotherapy and Oncology, 2015, 117, 193-194.	0.3	8
30	Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study. International Journal of Cancer, 2019, 145, 1325-1333.	2.3	8
31	Harmonization of breast cancer radiotherapy treatment planning in the Netherlands. Technical Innovations and Patient Support in Radiation Oncology, 2021, 19, 26-32.	0.6	8
32	Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapyâ€induced ovarian function failure. International Journal of Cancer, 2019, 145, 274-283.	2.3	7
33	Factors contributing to improved local control after mastectomy in patients with breast cancer aged 40 years or younger. Breast, 2010, 19, 44-49.	0.9	5
34	Elective breast radiotherapy including level I and II lymph nodes: A planning study with the humeral head as planning risk volume. Radiation Oncology, 2017, 12, 22.	1.2	5
35	Trends and variations in the treatment of stage I-III small cell lung cancer from 2008 to 2019: A nationwide population-based study from the Netherlands. Lung Cancer, 2021, 162, 61-70.	0.9	5
36	Salvage endoscopic resection in patients with esophageal adenocarcinoma after chemoradiotherapy. Endoscopy International Open, 2018, 06, E1126-E1129.	0.9	4

#	Article	IF	Citations
37	Predicting breast and axillary response after neoadjuvant treatment for breast cancer: The role of histology vs receptor status. Breast Journal, 2018, 24, 894-901.	0.4	4
38	Rate and predictors of nodal pathological complete response following neoadjuvant endocrine treatment in clinically biopsy-proven node-positive breast cancer patients. European Journal of Surgical Oncology, 2021, 47, 1928-1933.	0.5	4
39	Feasibility study of trastuzumab (T) and pertuzumab (P) added to neoadjuvant chemoradiotherapy (nCRT) in resectable HER2+ esophageal adenocarcinoma (EAC) patients (pts): The TRAP study.. Journal of Clinical Oncology, 2018, 36, 4057-4057.	0.8	4
40	Clinical evaluation of two AI models for automated breast cancer plan generation. Radiation Oncology, 2022, 17, 25.	1.2	4
41	Reduction of heart and lung normal tissue complication probability using automatic beam angle optimization and more generic optimization objectives for breast radiotherapy. Physics and Imaging in Radiation Oncology, 2021, 18, 48-50.	1.2	2
42	Anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure.. Journal of Clinical Oncology, 2017, 35, 523-523.	0.8	1
43	Response to â€œBenefit of Radiation Boost After Whole-Breast Radiotherapyâ€• (Int J Radiat Oncol Biol) Tj ETQq1 1 0.784314 rgBT /Ove	0.4	0
44	Assessment and management of bone health in women treated with adjuvant anastrozole in the DATA study.. Journal of Clinical Oncology, 2018, 36, 534-534.	0.8	0